07:00 Mon 12 Oct 2020
OptiBiotix Health - Launch of weight management products

OptiBiotix Health plc
("OptiBiotix" or the "Company")
Launch of weight management products in
Shakes and bars containing OptiBiome® technology
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the launch of meal replacement shakes and bars containing OptiBiotix's OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, ChemistWarehouse and on OptiPharm Pty Ltd's ("OptiPharm") online store in
These simultaneous launches build on a licence agreement entered into in
OptiPharm is a privately owned Australian company which has been operating for 24 years. OptiPharm's flagship brand, Optislim®, is the No. 1 Australian weight management brand incorporating shakes, soups and bars available as total (very low calorie diet) or partial (low calorie diet) meal replacements.
Dr.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc | ||
| Contact via Walbrook below | |
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
|
| |
|
| |
finnCap (Broker) | Tel: 020 7220 0500 | |
|
| |
|
| |
Walbrook PR Ltd | Mob: 07876 741 001 | |
|
| |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements, and health snacks and food products. The Company's current areas of focus include obesity, digestive health, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding OptiBiotix's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
FOR OUR FULL DISCLAIMER CLICK HEREDeep dive
